Overview

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

Status:
Unknown status
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to know the efficiency (costeffectiveness) at 48 weeks of initiation of antiretroviral treatment. three strategies of treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Juan A. Arnaiz
Treatments:
Abacavir
Cobicistat
Darunavir
Elvitegravir
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Lamivudine
Rilpivirine
Ritonavir
Tenofovir